AAAHC’s benchmarking study is based on clinical studies of YAG laser posterior capsulotomy surgeries between January and June 2018. The study includes 25 organizations with a combined 15,788 YAG laser ...

(RTTNews) - Innovent Biologics Inc. (IVBXF.OB) announced that the New Drug Application or NDA for ipilimumab injection (anti-CTLA-4 monoclonal antibody) has been accepted by the Center for Drug ...

This dual-immunotherapy neoadjuvant treatment regimen is mainly intended for patients with resectable stage IIB to III colon ...

NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon ...

Are you a member of an institution such as a university or hospital?Learn more about Institutional Access ...